Black individuals have experienced a consistent and dramatic disparity in prostate cancer death in the US over the past 50 years, despite advances in the diagnosis and treatment of prostate cancer.2,3,4 Level 1 evidence demonstrates a benefit to PSA screening,8,10 but previous studies have shown that rates of PSA screening have declined among Black individuals following the 2012 USPSTF PSA screening recommendation.13 Here, KLK3 is linked to prostate carcinoma.